JP2022527267A5 - - Google Patents

Info

Publication number
JP2022527267A5
JP2022527267A5 JP2021557228A JP2021557228A JP2022527267A5 JP 2022527267 A5 JP2022527267 A5 JP 2022527267A5 JP 2021557228 A JP2021557228 A JP 2021557228A JP 2021557228 A JP2021557228 A JP 2021557228A JP 2022527267 A5 JP2022527267 A5 JP 2022527267A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
sequence shown
hla
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021557228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527267A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/052776 external-priority patent/WO2020194195A1/en
Publication of JP2022527267A publication Critical patent/JP2022527267A/ja
Publication of JP2022527267A5 publication Critical patent/JP2022527267A5/ja
Priority to JP2025006913A priority Critical patent/JP2025062611A/ja
Withdrawn legal-status Critical Current

Links

JP2021557228A 2019-03-25 2020-03-24 T細胞受容体及びその使用方法 Withdrawn JP2022527267A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006913A JP2025062611A (ja) 2019-03-25 2025-01-17 T細胞受容体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962823487P 2019-03-25 2019-03-25
US62/823,487 2019-03-25
PCT/IB2020/052776 WO2020194195A1 (en) 2019-03-25 2020-03-24 T cell receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006913A Division JP2025062611A (ja) 2019-03-25 2025-01-17 T細胞受容体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2022527267A JP2022527267A (ja) 2022-06-01
JP2022527267A5 true JP2022527267A5 (cg-RX-API-DMAC7.html) 2023-03-17

Family

ID=72611623

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557228A Withdrawn JP2022527267A (ja) 2019-03-25 2020-03-24 T細胞受容体及びその使用方法
JP2025006913A Pending JP2025062611A (ja) 2019-03-25 2025-01-17 T細胞受容体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006913A Pending JP2025062611A (ja) 2019-03-25 2025-01-17 T細胞受容体及びその使用方法

Country Status (13)

Country Link
US (1) US12577287B2 (cg-RX-API-DMAC7.html)
EP (1) EP3947688A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022527267A (cg-RX-API-DMAC7.html)
KR (1) KR20210144782A (cg-RX-API-DMAC7.html)
CN (1) CN113795586B (cg-RX-API-DMAC7.html)
AU (1) AU2020245270A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018734A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133945A1 (cg-RX-API-DMAC7.html)
IL (1) IL286620A (cg-RX-API-DMAC7.html)
MX (1) MX2021011462A (cg-RX-API-DMAC7.html)
SG (1) SG11202109701SA (cg-RX-API-DMAC7.html)
TW (1) TW202102533A (cg-RX-API-DMAC7.html)
WO (1) WO2020194195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110950949B (zh) * 2018-09-26 2022-04-05 香雪生命科学技术(广东)有限公司 一种识别ssx2抗原的t细胞受体
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof
CN112442119B (zh) * 2019-09-05 2023-02-24 香雪生命科学技术(广东)有限公司 一种识别ssx2的高亲和力t细胞受体
MX2024005746A (es) * 2021-11-10 2024-07-19 Tscan Therapeutics Inc Peptidos inmunogenicos magea1, proteinas de union que reconocen peptidos inmunogenicos magea1, y usos de estos.
CN116063458A (zh) * 2022-04-27 2023-05-05 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
CN117986350B (zh) * 2023-02-23 2024-08-16 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
KR20260100669A (ko) * 2023-10-27 2026-06-30 티스캔 테라퓨틱스, 인크. Magea1 면역원성 펩티드, magea1 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
CA2682093A1 (en) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
EP3031916B1 (en) * 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
US8785601B2 (en) * 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2010112962A1 (en) * 2009-04-02 2010-10-07 Vaxon Biotech Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
US9314516B2 (en) 2010-05-04 2016-04-19 Cassian Yee Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
ES2635335T3 (es) 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
JP6895975B2 (ja) 2016-01-06 2021-06-30 ヘルス リサーチ インコーポレイテッドHealth Research, Inc. 組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
JP6692040B2 (ja) * 2016-11-01 2020-05-13 学校法人自治医科大学 成人t細胞性白血病を含むhtlv−1ウイルス感染に対する腫瘍抗原特異的t細胞
US12522644B2 (en) 2019-03-04 2026-01-13 University Health Network T cell receptors and methods of use thereof
AU2020231927A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
BR112021017404A2 (pt) 2019-03-04 2022-02-01 Univ Health Network Receptores de células t e métodos de uso dos mesmos
CA3132434A1 (en) 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
EP3935173A4 (en) 2019-03-04 2023-05-31 University Health Network T-CELL RECEPTORS AND METHODS OF USE THEREOF
MX2021010537A (es) 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
CA3133945A1 (en) 2019-03-25 2020-10-01 University Health Network T cell receptors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022524993A5 (cg-RX-API-DMAC7.html)
JP2022523971A5 (cg-RX-API-DMAC7.html)
JP2022523552A5 (cg-RX-API-DMAC7.html)
JP2022524994A5 (cg-RX-API-DMAC7.html)
JP2022523554A5 (cg-RX-API-DMAC7.html)
JP2022523553A5 (cg-RX-API-DMAC7.html)
JP2022524992A5 (cg-RX-API-DMAC7.html)
Kandalaft et al. Immunotherapy for ovarian cancer: what's next?
Kershaw et al. Gene-engineered T cells for cancer therapy
Baxevanis et al. Cancer immunotherapy
Batlevi et al. Novel immunotherapies in lymphoid malignancies
CN106459990B (zh) 三功能t细胞抗原偶联物及其制备方法和用途
Merhavi-Shoham et al. Adoptive cell therapy for metastatic melanoma
JP2022543059A5 (cg-RX-API-DMAC7.html)
JP2020509767A5 (cg-RX-API-DMAC7.html)
Essand et al. Genetically engineered T cells for the treatment of cancer
CN111629734A (zh) 用于共刺激的新型平台、新型car设计以及过继性细胞疗法的其他增强
Tsang et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
JP2017523784A5 (cg-RX-API-DMAC7.html)
CN113785065B (zh) T细胞受体及其使用方法
CN108138148A (zh) T细胞的激活和扩增
JP2023512452A (ja) Bcma指向性細胞免疫療法組成物および方法
TW201726149A (zh) 用於免疫療法之組合方法
CN115747156A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors